C.Q. Pharmaceutical Holding Co., Ltd. (SHE:000950)
China flag China · Delayed Price · Currency is CNY
6.03
+0.03 (0.50%)
At close: Feb 6, 2026

SHE:000950 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Jan '23 Dec '21 Dec '20
Operating Revenue
82,77380,25578,18567,65762,35445,104
Other Revenue
307.01307.01212.62171.83166.87115.37
83,08080,56278,39767,82962,52145,220
Revenue Growth (YoY)
4.23%2.76%15.58%8.49%38.26%33.61%
Cost of Revenue
77,10974,64172,16262,03856,81741,012
Gross Profit
5,9715,9216,2355,7915,7034,207
Selling, General & Admin
3,8193,9673,6783,2983,0782,218
Research & Development
-8.140.320.383.2410.042.67
Other Operating Expenses
218.21189.22212.55188.63155.73123.62
Operating Expenses
4,7804,6884,2793,6143,5262,446
Operating Income
1,1911,2321,9572,1772,1771,762
Interest Expense
-863.54-1,138-1,340-1,123-1,106-675.52
Interest & Investment Income
367.06488.19393.27355.29347.92325.03
Currency Exchange Gain (Loss)
-0.17-0.170.180.44-0.10.43
Other Non Operating Income (Expenses)
-46.96-41.03-103.03-12.363.66-104.4
EBT Excluding Unusual Items
647.78541.54906.961,3971,4231,307
Impairment of Goodwill
-40.22-40.22-20.48-27.91-10.32-14.68
Gain (Loss) on Sale of Investments
-0.996.9216.162.32126.8817.45
Gain (Loss) on Sale of Assets
11.2310.530.7910.053.5221.54
Asset Writedown
-10.060.01-0.01-0.02-0.35-
Other Unusual Items
60.1238.7362.9191.2537.3542.89
Pretax Income
667.86557.51966.331,4721,5801,374
Income Tax Expense
140.54155.72236.04309.5289.61227.07
Earnings From Continuing Operations
527.33401.79730.291,1631,2911,147
Net Income to Company
527.33401.79730.291,1631,2911,147
Minority Interest in Earnings
-152.55-118.8-105.65-210.72-285.23-263.05
Net Income
374.78282.99624.63952.281,005884.34
Net Income to Common
374.78282.99624.63952.281,005884.34
Net Income Growth
-6.13%-54.69%-34.41%-5.29%13.69%12.22%
Shares Outstanding (Basic)
1,7891,7691,7351,7311,7341,728
Shares Outstanding (Diluted)
1,7891,7691,7351,7311,7341,728
Shares Change (YoY)
3.37%1.94%0.21%-0.12%0.31%-
EPS (Basic)
0.210.160.360.550.580.51
EPS (Diluted)
0.210.160.360.550.580.51
EPS Growth
-9.19%-55.56%-34.54%-5.17%13.73%11.85%
Free Cash Flow
324.79-437.27264.1317.76-239.38253.82
Free Cash Flow Per Share
0.18-0.250.150.01-0.140.15
Dividend Per Share
0.0600.0600.0500.0600.105-
Dividend Growth
-25.00%20.00%-16.67%-42.86%--
Gross Margin
7.19%7.35%7.95%8.54%9.12%9.30%
Operating Margin
1.43%1.53%2.50%3.21%3.48%3.90%
Profit Margin
0.45%0.35%0.80%1.40%1.61%1.96%
Free Cash Flow Margin
0.39%-0.54%0.34%0.03%-0.38%0.56%
EBITDA
1,4381,4792,2032,4082,3461,886
EBITDA Margin
1.73%1.84%2.81%3.55%3.75%4.17%
D&A For EBITDA
246.4246.6246.87231.17169.06124.75
EBIT
1,1911,2321,9572,1772,1771,762
EBIT Margin
1.43%1.53%2.50%3.21%3.48%3.90%
Effective Tax Rate
21.04%27.93%24.43%21.02%18.33%16.52%
Revenue as Reported
83,08080,56278,39767,82962,52145,220
Advertising Expenses
-9.429.5720.3923.4914.21
Source: S&P Global Market Intelligence. Standard template. Financial Sources.